SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Sep 14, 2021--

Regulatory News:

Median Technologies (ALMDT: PA) will announce its H1 2021 results as well as its Q3 2021 business performance indicators on October 21, 2021 after trading close instead of October 14, 2021 after trading close.

About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics to provide insights into novel therapies and treatment strategies. Our unique solutions for medical image analysis and management in oncology trials and iBiopsy ® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label “Innovative company” by the BPI and is listed on the Euronext Growth market. FR0011049824– ticker: ALMDT. Median is eligible for the French SME equity savings plan scheme (PEA-PME), listed on the Enternext ® PEA-PME 150 index and has been awarded the Euronext European Rising Tech label. For more information: www.mediantechnologies.com

CONTACT: Median Technologies

Emmanuelle Leygues

Head of Corporate and Marketing Communications

+33 6 10 93 58 88

Caroline Carmagnol

+33 6 64 18 99 59

Ghislaine Gasparetto

+33 1 56 88 11 11

KEYWORD: FRANCE EUROPE

INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH RADIOLOGY PHARMACEUTICAL ONCOLOGY

SOURCE: Median Technologies

Copyright Business Wire 2021.

PUB: 09/14/2021 02:30 AM/DISC: 09/14/2021 02:31 AM

Recommended For You


Copyright Business Wire 2021.

Tags